Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...
Le Lézard

Minutes from Extraordinary General Meeting in FluoGuide A/S

KØBENHAVN, DK / ACCESS Newswire / November 24, 2025 / FluoGuide A/S (STO:FLUO)("FluoGuide" or the "Company" held an extraordinary general meeting on 24 November 2025.To the shareholders of FluoGuide A ...
The RINJ Foundation

Support Safety for women, girls and special needs in war zones

RINJ claims full and unfettered freedom in the exercise of its functions.

Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved as the First Targeted ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...